DistantNews
🇹🇼 Taiwan /Health & Science

Taiwanese stem cell drug to be presented at international conference

From Liberty Times · (8m ago) Chinese Positive tone

Translated from Chinese, summarized and contextualized by DistantNews.

TLDR

  • Taiwanese biotech company Medigen's stem cell drug ELIXCYTE®-CKD, for treating chronic kidney disease, will be presented at the International Society for Cellular Therapy (ISCT) annual meeting.
  • Medigen is the only Taiwanese company invited for an oral presentation in the stem cell category, marking a significant international exposure for Taiwan's research.
  • The drug has received Fast Track designation from the US FDA, potentially accelerating its development and review process.

In a significant achievement for Taiwan's burgeoning biotechnology sector, Medigen's groundbreaking stem cell therapy for chronic kidney disease, ELIXCYTE®-CKD, has been selected for an oral presentation at the prestigious International Society for Cellular Therapy (ISCT) annual meeting. This invitation, a first for a Taiwanese company in the stem cell category, places Medigen and Taiwan's innovative research firmly on the global stage. It's a moment of national pride, showcasing our nation's capability in advanced medical research and development.

The ISCT annual meeting is a premier global forum, attracting leading clinicians, regulators, researchers, and industry experts. Medigen's presentation, scheduled for May 8th, will highlight the promising results from its Phase 1/2 clinical trials. The data suggests that ELIXCYTE®-CKD has the potential to slow the progression of chronic kidney disease, particularly in high-risk patient populations. This recognition at such a high-profile international conference validates the rigorous scientific work undertaken by our local researchers and clinicians.

Furthermore, ELIXCYTE®-CKD's recent designation as 'Fast Track' by the US Food and Drug Administration (FDA) in March 2025 is a testament to its potential to address significant unmet medical needs. This designation is crucial as it expedites the drug's development and review process, bringing this potentially life-changing therapy closer to patients. For Taiwan, this is not just a scientific breakthrough but also a strategic advancement in our ambition to become a leader in the global biopharmaceutical industry. The success of companies like Medigen reinforces our commitment to fostering innovation and supporting our homegrown scientific talent.

Clinical Development of Allogeneic Adipose-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease: An Integrated Translational Evidence Framework

— MedigenThe title of the presentation for ELIXCYTE®-CKD at the ISCT annual meeting.
DistantNews Editorial

Originally published by Liberty Times in Chinese. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog